Opinion of the Transparency Council – budesonideum
At its meeting on 16 December 2024, the Transparency Council adopted opinion No. 202/2024 on the inclusion in reimbursement of medicines containing the active substance budesonideum in the scope of indications for use or dosage or mode of administration different from those specified in the Summary of Product Characteristics, i.e. viral laryngitis in children under 18 years of age